Sign in
TerminatedNo phase

Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete Responders

Key facts

Who runs it
Henry Ford Health System
Where
Detroit, United StatesSee the site
Trial code
Status
Terminated
People taking part
15 people enrolled
Started
26 Feb 2016
Ended
1 Apr 2025
Type of study
Interventional
Treatments tested
  • Standard of care chemotherapy with the change for avoidance of extensive surgery
Record updated
23 July 2026
Why it stopped
Lack of financial support

Who can take part

Age
18 years to 95 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Diagnosis of rectal invasive adenocarcinoma
  • Tumor in the low or mid rectum (up to 11 cm from the anal verge)
  • Clinical stage T3/N0-N1M0. Patients with low T2 who will need abdominal perineal resection are also eligible
  • Clinical staging will be estimated based on the combination of the following assessments:
  • Physical examination by the primary surgeon
  • Computed Tomography or Positron Emission Tomography/Computed Tomography scan of chest, abdomen and pelvis
  • Pelvic MRI and endoscopic ultrasound

Who cannot take part

  • Less than 18 years of age
  • Do not complete informed consent
  • Pregnant women

Where in United States

  • Ascension St. John HospitalDetroit, United States

About the trial

What the trial wants to find out

The current standard of care for rectal cancer has diminished local recurrence and enhanced survival. Quality of life, however, remains poor for many patients and the probability of distant recurrence is high. In this study, we will attempt to reduce the distant recurrence rate and improve quality of life by making changes in the timing and administration of chemotherapy and radiation and doing less invasive rectal surgery when indicated.

The group in the trial

  • Neoadjuvant Chemotherapy and Follow-up SurgeryOther group

    All patients will receive standard of care therapy and based upon their response will either receive transanal local resection or full resection, based on pathologic response.

    Treatment: Standard of care chemotherapy with the change for avoidance of extensive surgery

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Treatment of T2-T3/NO-N+ Adenocarcinoma of the Rectum by Neoadjuvant Chemotherapy (FOLFOX) Followed by Preoperative Chemo (5FU/Capecitabine)-Radio Therapy (CRT) With Transanal Local Excision for Complete Responders
Record updated
23 July 2026